Biocon Biologics’ Ratings Unaffected by Buyout of Minorities – Fitch Ratings

Written by

admin

in

  1. Biocon Biologics’ Ratings Unaffected by Buyout of Minorities  Fitch Ratings
  2. Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion  Forbes
  3. Cyril Amarchand Mangaldas advises Serum Institute on sale of stake held in Biocon Biologics and subscription of shares in Biocon Limited, through share swap  SCC Online
  4. Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?  Citeline News & Insights
  5. Biocon Limited to integrate Biocon Biologics  The Pharma Letter

Continue Reading

More posts